Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Adaptation to an acid microenvironment promotes pancreatic cancer organoid growth and drug resistance

ABSTRACT: Adaptation to an acid microenvironment promotes pancreatic cancer organoid growth and drug resistance

PROVIDER: PRJNA902673 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR22319900.fastq.gz	Fastqsanger.gz
	SRR22319901.fastq.gz	Fastqsanger.gz
	SRR22319902.fastq.gz	Fastqsanger.gz
	SRR22319903.fastq.gz	Fastqsanger.gz
	SRR22319904.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 183

Similar Datasets

Adaptation to an acid microenvironment promotes pancreatic cancer organoid growth and drug resistance [drug]

Project description:Adaptation to an acid microenvironment promotes pancreatic cancer organoid growth and drug resistance [drug]

| PRJNA902680 | ENA

Adaptation to an acid microenvironment promotes pancreatic cancer organoid growth and drug resistance [acid]

Project description:Adaptation to an acid microenvironment promotes pancreatic cancer organoid growth and drug resistance [acid]

| PRJNA902671 | ENA

Adaptation to an acid microenvironment promotes pancreatic cancer organoid growth and drug resistance [acid]

Project description:We investigated transcriptomic changes in pancreatic ductal organoids under adaptation to an acidic extracellular environment.

2024-06-04 | GSE218173 | GEO

Adaptation to an acid microenvironment promotes pancreatic cancer organoid growth and drug resistance [drug]

Project description:We investigated transcriptomic changes in PanIN ("mP4") mouse pancreatic ductal organoids under acute or long-term treatment of Gemcitabine and Erlotinib.

2024-06-04 | GSE218177 | GEO

Adaptation to an acid microenvironment promotes pancreatic cancer organoid growth and drug resistance

Project description:This SuperSeries is composed of the SubSeries listed below.

2024-06-04 | GSE218178 | GEO

Organoid modeling of the tumor immune microenvironment

Project description:Organoid modeling of the tumor immune microenvironment

| PRJNA436710 | ENA

Precision Chemotherapy Based on Organoid Drug Sensitivity for Colorectal Cancer

Project description:The purpose of this study is to investigate whether chemotherapy guided by patient-derived tumor organoid drug test can improve the outcomes of stage IV colorectal cancer.

| 58056 | ecrin-mdr-crc

A three-dimensional organoid model recapitulates tumorigenic aspects and drug responses of advanced human retinoblastoma

Project description:Persistent or recurrent retinoblastoma (RB) is associated with the presence of vitreous or/and subretinal seeds in advanced RB and represents a major cause of therapeutic failure. This necessitates the development of novel therapies and thus requires a model of advanced RB for testing candidate therapeutics. To this aim, we established and characterized a three-dimensional, self-organizing organoid model derived from chemotherapy-naïve tumors. The responses of organoids to drugs were determined and compared to relate organoid model to advanced RB, in terms of drug sensitivities. We found that organoids had histological features resembling retinal tumors and seeds and retained DNA copy-number alterations as well as gene expression profile and protein expression of the parental tissue. Cone signal circuitry (M/L+ cells) and glial tumor microenvironment (GFAP+ cells) were primarily present in organoids. Topotecan alone or the combined drug regimen of topotecan and melphalan effectively targeted proliferative tumor cones (RXRg+ Ki67+) in organoids after 24-h drug exposure, blocking mitotic entry. In contrast, methotrexate showed the least efficacy against tumor cells. The drug responses of organoids were consistent with those of tumor cells in advanced disease. Patient-derived organoids enable the creation of a faithful model to use in examining novel therapeutics for RB.

2018-10-23 | GSE120710 | GEO

Mimicking tumor cell heterogeneity of colorectal cancer in a patient-derived organoid-fibroblast model

Project description:Patient derived organoids (PDOs) have been established as a 3D culture model which closely recapitulates the in vivo tumor biology. However, one limitation of this culture model is the lack of tumor microenvironment which has a significant role in tumor progression and drug response. To address this, we established and molecularly characterized a novel 3D co-culture model of colorectal cancer (CRC) based on PDOs and patient matched fibroblasts. Both normal and cancer associated fibroblasts, NFs and CAFs respectively, were able to support organoid growth without addition of niche factors to the media. Additionally, co-cultures showed closer resemblance to primary patient material than organoid mono-cultures as evaluated by histology. Finally, RNA gene expression signatures of tumor cells and fibroblasts isolated from mono- or co-cultures demonstrated that co-cultures support greater cell type heterogeneity. In this proteomics dataset we compared pairs of NFs and CAFs derived from five patients. Collectively, we present a newly established human derived organoid-fibroblast model which, closely recapitulates in vivo tumor heterogeneity and involves the tumor microenvironment.

2023-03-14 | PXD032047 | Pride

A novel pancreatic ductal adenocarcinoma organoid recapitulating tumor microenvironment reveals macrophage-driven enhanced cancer cell survival [RNA-Seq]

Project description:Pancreatic ductal adenocarcinoma (PDAC) is a progressive cancer with only about 12 % of a 5-year survival rate. PDAC generally shows strong chemoresistance, which has been correlated with the tumor microenvironment (TME) of PDAC consisting of various types of stromal cells. Recent single-cell RNA sequence (scRNAseq) analyses demonstrate that a high percentage of myeloid cells in TME stroma cells is related to poor prognosis, and, among myeloid cells, tumor associated macrophages (TAM) are the most abundant population. However, their functions in PDAC malignancy remain largely unknown. Previously, we established a PDAC-organoid associated with an artificial TME by co-culturing patient-derived cancer cells, human induced pluripotent stem cell (hiPSC) derived mesenchymal and endothelial cells, which is called fused pancreatic cancer organoid (FPCO). Here, we further incorporated macrophages into FPCO and named it M0-FPCO. After 1 week of organoid culture, the macrophages in M0-FPCO expressed the conventional markers of M2-macrophages, such as CD163 and CD206. However, bulk RNAseq analysis showed that macrophages in M0-FPCO (FPCO-Mac) have distinct characteristics as compared with M2-macrophages induced with IL4 and 13. scRNAseq of M0-FPCO further demonstrated that FPCO-Mac was divided into 6 populations including Granulin+-TAM and SPP1+-TAM, which had been identified in human PDAC tissue. Furthermore, the number of PDAC cells was reduced in FPCO but not in M0-FPCO between 1 and 2 weeks of organoid culture, suggesting that cancer cells could survive longer or are protected from cell death in the presence of TAM. Moreover, the bulk-RNAseq analysis of the surviving M0-FPCO unveiled a GALE potentially associated with a worse prognosis in PDAC patients. Our novel PADC organoid including macrophage (M0-FPCO) replicated the PDAC-TAM features and elucidated their protumorigenic function.

2024-12-01 | GSE249672 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data